Short Interest in Nuvilex Inc. (NASDAQ:PMCB) Expands By 181.9%

Nuvilex Inc. (NASDAQ:PMCB) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 177,318 shares, a growth of 181.9% from the December 31st total of 62,893 shares. Approximately 2.0% of the company’s stock are short sold. Based on an average trading volume of 459,349 shares, the days-to-cover ratio is currently 0.4 days. Based on an average trading volume of 459,349 shares, the days-to-cover ratio is currently 0.4 days. Approximately 2.0% of the company’s stock are short sold.

Insider Activity

In other Nuvilex news, CEO Joshua Silverman purchased 40,000 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were acquired at an average price of $0.83 per share, for a total transaction of $33,200.00. Following the completion of the purchase, the chief executive officer owned 416,250 shares of the company’s stock, valued at approximately $345,487.50. The trade was a 10.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have purchased 110,000 shares of company stock valued at $89,000. 10.33% of the stock is owned by insiders.

Nuvilex Stock Performance

Nuvilex stock opened at $0.82 on Friday. The company has a market capitalization of $8.30 million, a P/E ratio of -0.59 and a beta of 0.04. Nuvilex has a fifty-two week low of $0.63 and a fifty-two week high of $1.90. The stock has a 50-day simple moving average of $0.87 and a 200-day simple moving average of $0.92.

Nuvilex (NASDAQ:PMCB) last announced its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research note on Thursday, January 22nd. Wall Street Zen upgraded Nuvilex to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.